



What is the PRISM 3 study?

The PRISM 3 clinical research study is for patients who have had a recurrence of *Clostridium difficile* infection (CDI or *C. diff*). The study will evaluate the safety and effectiveness of the study drug to prevent recurrence of CDI compared against placebo.

What is the study drug?

The study drug (CP101, Full-Spectrum Microbiota™) is an investigational drug designed to deliver gut bacteria from healthy human stool donors to your intestine. This gut bacteria may help overtake the surplus of *C. diff* bacteria that cause CDI. CP101 is considered “investigational” because it has not been approved by the US Food and Drug Administration for treating CDI.

For more information about the PRISM 3 study, please contact:

Borland Groover

Phone: 904-680-0871

research@borlandgroover.com


Learn more about the PRISM 3 clinical research study.



Study Drug CP101

How is CP101 different than a fecal transplant?

CP101 is a Full-Spectrum Microbiota™, FSM™, therapy that is encapsulated for oral administration. CP101 builds on the science of fecal transplants with technology licensed from the University of Minnesota and insight from OpenBiome. These capsules are odorless and contain gut bacteria in the form of a freeze-dried powder. The powder is intended to be released from the capsules in the right part of your intestine where the bacteria may repopulate. This may aid in restoring the diverse community of bacteria found in the healthy human gut, which may prevent recurrence of *C. diff*.



Who can participate in the study?

You may be eligible to participate in PRISM 3 if you meet these criteria*:

- 18 years of age or older
- Have had a previous episode of CDI
- Responded to CDI antibiotic therapy for the most recent CDI episode
- Do not have a history or diagnosis of irritable bowel disease (IBD) or irritable bowel syndrome (IBS)

*Other criteria will apply.

What can study participants expect?

If you join the PRISM 3 study, you will:

- Be randomly assigned to receive either a single dose of 10 capsules of the study drug or placebo (no active ingredients) on Day 1 of the study
- Attend follow-up visits for 24 weeks after receiving the study drug or placebo
- Provide a stool sample (using at-home collection kit) throughout the study
- All patients (including patients receiving placebo) will have an opportunity to receive study drug if they experience a recurrence through our open-label study

Study staff experienced in clinical trials will monitor your health throughout the study.

What you help us learn from the PRISM 3 study may help improve the standard of care in the future for thousands of patients like you, who are suffering from CDI.

PRISM 3 may give you a chance to fight back against CDI.

How can I learn more about the PRISM 3 trial?

The PRISM 3 study team is available to answer any questions you may have about the study or investigational drug, CP101. Please refer to the contact information on the back cover of this brochure.